Camelids such as llama and camel develop two non-canonical IGs with the conformist IgG1, IgG2, IgG3 that are called heavy-chain antibodies. They all have one single domain binding site known as VHH and do not have any light chains or a CH1 domain. These antibodies have docile features that make them convenient in many medical trials such as the diagnostic and treatment of cancer.
Goat
anti-llama Alkaline Phosphatase can be used at
specific stages of recombinant development of VHH antibodies to augment and
accelerate the high-affinity VHH antibodies.
VHH antibodies and their Applications: VHH antibodies are a
resultant of the VHH domain of heavy chain goat
anti-llama HRP IgG.
Being beneficial, Nanobodies (VHH antibodies) have now become the first choice
of many fields. Uses of these antibodies consist of various applications, for
example, biosensors, detection of small molecules, crystallization partners,
therapeutics, and medical diagnostics.
Reimbursements of Goat anti-llama Alkaline
Phosphatase derived VHH antibodies
Therapeutic Reimbursements: VHH antibodies have
the potential to cross the blood-brain barricade and can access other isolated
locations that make them helpful for drug delivery. Their excellent stability
lets them deliver drugs through different routes that include subcutaneous and
intravenous injections, oral ingestion, and nasal inhalation.
Stability: We have just talked about the stability of VHH
antibodies that helps deliver drugs through different pathways. Goat
anti-llama HRP IgG-derived VHH antibodies also are tolerant to heat and
have good solubility, PH extremes, and peptidases.
No comments:
Post a Comment